Skip to main content
. Author manuscript; available in PMC: 2024 Jul 11.
Published in final edited form as: Adv Funct Mater. 2023 Apr 14;33(28):2300218. doi: 10.1002/adfm.202300218

Figure 3. Pharmacokinetics of TBI-ABN in mice.

Figure 3.

a. Nanosensor was intravenously administered in uninjured mice, and blood and urine samples were collected at multiple time-points after injection. b. Blood circulation half-life of free calpain substrate in the blood of uninjured mice, as measured by ELISA (n = 2 for 1 and 3 min; n = 4 for 7, 15, 30, 60, and 120 min; mean ± SE, two-phase decay). c. Estimated accumulation of free calpain substrate in the urine of uninjured mice at 1 h post-injection, as measured by ELISA (n = 4, mean ± SE). d. Blood circulation half-life of TBI-ABN tagged with VT750 in uninjured mice, as measured by fluorescence of VT750 (n = 5, mean ± SE). e. Accumulation of TBI-ABN tagged with VT750 in urine of uninjured mice at 1 h post-injection, as measured by fluorescence of VT750 (n = 5, mean ± SE).